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ABSTRACT
Introduction: The fixed-ratio combinations
(FRCs) of glucagon-like peptide 1 receptor ago-
nists (GLP-1 RAs) and basal insulin, insulin
glargine 100 U/mL plus lixisenatide (iGlarLixi),
and insulin degludec plus liraglutide (iDegLira),
have demonstrated safety and efficacy in
patients with type 2 diabetes mellitus (T2DM)
inadequately controlled on GLP-1 RAs. How-
ever, a comparative cost-effectiveness analysis
between these FRCs from a UK Health Service
perspective has not been conducted.
Methods: The IQVIA Core Diabetes Model was
used to estimate lifetime costs and outcomes in
patients with T2DM receiving iGlarLixi (based
on the LixiLan-G trial) versus iDegLira (based on
relative treatment effects from an indirect
treatment comparison using data from
DUAL III). Utilities, medical costs, and costs of
diabetes-related complications were derived
from literature. Model outputs included costs
and quality-adjusted life years (QALYs). Incre-
mental cost-effectiveness ratios were calculated
with a local willingness-to-pay threshold of
£20,000 per QALY. Extensive scenario, one-way
sensitivity, and probabilistic sensitivity analyses
were conducted to evaluate the robustness of
the model.
Results: iGlarLixi was less costly (iGlarLixi,
£30,011; iDegLira, £40,742), owing to lower
acquisition costs, and similar in terms of QALYs
gained (iGlarLixi, 8.437; iDegLira, 8.422).
Extensive scenario and sensitivity analyses
supported the base case findings.
Conclusion: In patients with T2DM and inad-
equate glycemic control despite GLP-1 RAs, use
of iGlarLixi was associated with substantial cost
savings and comparable utility outcomes.
iGlarLixi can be considered as cost-effective
versus iDegLira from the UK Health Service
perspective.
Keywords: Cost-effectiveness; Cost-utility;
GLP-1 receptor agonist; iGlarLixi; Type 2
diabetes mellitus; United Kingdom
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Key Summary Points
Individuals with type 2 diabetes mellitus
(T2DM) inadequately controlled on
glucagon-like peptide 1 receptor agonists
(GLP-1 RAs) often require treatment
intensification with dual or triple therapy.
To facilitate co-administration of more
than one antidiabetic therapy, fixed-ratio
combination (FRC) of insulin glargine
100 U/mL (iGlar) plus lixisenatide
(iGlarLixi; Suliqua), and insulin
degludec plus liraglutide (iDegLira;
Xultophy) have been developed and
have demonstrated efficacy compared
with continuation of GLP-1 RAs in
individuals with T2DM.
This cost-effectiveness analysis compared
these FRCs in patients inadequately
controlled on GLP1-RAs from a UK Health
Service perspective
iGlarLixi was less costly (iGlarLixi,
£30,011; iDegLira, £40,742) owing to
lower acquisition costs, and similar in
terms of QALYs gained (iGlarLixi, 8.437;
iDegLira, 8.422), which was supported by
results of scenario and sensitivity analyses.
Thus, in patients with T2DM and
suboptimal glycemic control on GLP-1 RA
therapy, iGlarLixi was associated with
substantial cost savings and comparable
utility outcomes compared with iDegLira,
and was considered cost-effective over a
lifetime time horizon
INTRODUCTION
Guidelines from the American Diabetes Associ-
ation (ADA) and the European Association for
the Study of Diabetes (EASD) recommend glu-
cagon-like peptide 1 receptor agonists (GLP-
1 RAs) as first injectable medications for indi-
viduals with glycated hemoglobin (HbA1c)
above their individual targets [1, 2]. In 2019, the
ADA/EASD updated their guidance to also rec-
ommend GLP-1 RA for individuals with type 2
diabetes mellitus (T2DM) at high risk of car-
diovascular disease, independent of their gly-
cemic control, in order to reduce the risk for
major cardiovascular events [1]. Despite clear
evidence for the efficacy of GLP-1 RA, a signifi-
cant proportion of patients receiving GLP-1 RA
do not experience lasting glycemic control and
require treatment intensification [3, 4].
To facilitate co-administration of more than
one antidiabetic therapy, fixed-ratio combina-
tion (FRC) products have been developed with
the aim of simplifying treatment regimens
compared with co-administration of individual
therapies [5, 6]. As such, FRCs of insulin glar-
gine 100 U/mL (iGlar) plus lixisenatide (iGlar-
Lixi; Suliqua), and insulin degludec plus
liraglutide (iDegLira; Xultophy) have been
developed and have demonstrated proven effi-
cacy compared with continuation of GLP-1 RAs
in patients inadequately controlled on GLP-
1 RAs and other oral antidiabetic drugs (OADs)
[7, 8]. The randomized, open-label LixiLan-G
trial (NCT02787551) demonstrated that
switching to iGlarLixi improved glucose control
compared with continuing treatment with
once- or twice-daily or once-weekly GLP-1 RA,
in patients with T2DM insufficiently controlled
on a maximum tolerated dose of GLP-1 RA plus
metformin and other OADs [7]. The open-label
DUAL III trial (NCT01676116), evaluating iDe-
gLira versus continued use of previous liraglu-
tide or exenatide therapy in patients with T2DM
insufficiently controlled on a maximum toler-
ated dose of GLP-1 RA, demonstrated improved
glycemic control compared with unchanged
GLP-1 RA [8].
Although a direct head-to-head comparison
of different FRCs in patients with inadequate
glycemic control while receiving GLP-1 RA is
lacking, an indirect treatment comparison (ITC)
reported no significant differences in HbA1c
target attainment, pre-prandial, or postprandial
self-monitored plasma glucose for patients
using either iGlarLixi or iDegLira [9]. The mean
differences (95% CI) in blood glucose parame-
ters between iDegLira and iGlarLixi were -
0.36% (- 0.58 to - 0.14) for HbA1c
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and - 1.0 mmol/L (- 1.57 to - 0.43) for fast-
ing plasma glucose, favoring iDegLira, at
week 26 [9]. In both primary trials an increase in
body weight was noted in the FRC group rela-
tive to the comparator arm, which continued
with GLP-1 RA therapy [7, 8]; however, body
weight change was not significantly different
between iDegLira and iGlarLixi at week 26 in
the ITC (- 0.23 kg [- 1.14 to 0.67]) [9]. Formal
comparisons of hypoglycemia were unfortu-
nately limited by differences in definitions
between the two studies. To address increasing
pressure on heathcare system expenditures,
healthcare value has to be considered as part of
decision-making. Economic evaluations are
critical for decision-making processes and
maximizing resource allocation. The present
study sought to compare the cost-effectiveness
of FRC iGlarLixi with FRC iDegLira, using the
IQVIA Core Diabetes Model (CDM).
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
METHODS
Study Overview
The clinical setting for this model was patients
with T2DM who have inadequately controlled
HbA1c while on GLP-1 RA and OADs, in line
with the LixiLan-G trial cohort [7]. Patients
were entered into the model with HbA1c[
7.8%, and with baseline characteristics based
on a weighted average from the LixiLan-G
clinical trial [7] (see the Electronic Supplemen-
tary Material [ESM] Table S1). Treatment effects
from LixiLan-G were used to model initial
responses to iGlarLixi therapy. Relative treat-
ment effect for iDegLira was based on a previ-
ously published ITC comparing iGlarLixi and
iDegLira (Table 1) [9]. Long-term clinical and
cost outcomes were predicted by the IQVIA
CDM version 9.5. The CDM is a validated, non-
product-specific analysis tool that models the
effect of glucose monitoring, diabetes therapies,
screening, and treatment strategies for
microvascular complications, treatment
strategies for end-stage complications, and
potential intervention sequences. The IQVIA
CDM has been extensively validated and is
widely used in diabetes research [10–12].
Disease progression in the CDM is predicted
on the basis of a series of interdependent Mar-
kov sub-models that simulate progression of
disease-related complications using a set of
equations for progression of the disease risk
factors (United Kingdom Prospective Diabetes
Study [UKPDS] Outcomes Model no. 68 UKPDS
68]) [13] and for predicting the cardiovascular
and mortality risk (UKPDS 82) [14]. Each sub-
model uses time-, state- and diabetes type-de-
pendent probabilities. This cost-effective-
ness/cost-utility analysis was conducted from
the perspective of the UK National Health Ser-
vice (NHS), assuming a willingness-to-pay








on ITC by Home
2020) [9]
HbA1c, % (SD) - 1.02 (0.05) - 1.38 (0.10)










BMI body mass index, HbA1c glycated hemoglobin, iDe-
gLira insulin degludec plus liraglutide, iGlarLixi insulin
glargine 100 U/mL plus lixisenatide, ITC indirect treat-
ment comparison, LSM least squares mean, PY patient-
year, SD standard deviation
a BMI change from baseline was estimated from body
weight change from baseline
b Defined as symptomatic with plasma glucose\ 54 mg/
dL (\ 3.0 mmol/L) for iGlarLixi; B 56 mg/dL
(B 3.1 mmol/L) regardless of symptoms or severity for
iDegLira
c As reported in iDegLira Dual III trial
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(WTP) threshold of £20,000/quality-adjusted
life year (QALY), and used a hypothetical cohort
of 1000 patients with a lifetime time horizon;
1000 model iterations were run, and annual
discounting rates of 3.5% for costs and out-
comes were used in line with UK National
Institute of Health and Care Excellence Deci-
sion Support Unit guidance [15].
Model Inputs and Structure
The impact of iGlarLixi on risk factors (HbA1c,
body mass index [BMI], symptomatic and severe
hypoglycemia event rates) were applied from
the LixiLan-G study (Table 1). For the compar-
ison with iDegLira, the absolute HbA1c treat-
ment effect was derived from the relative
treatment effects reported by Home et al. [9]
(Table 1). The HbA1c treatment effect of iDe-
gLira was calculated by applying the difference
obtained from ITC (- 0.36% [- 0.58 to - 0.14])
to the treatment effect for iGlarLixi. Patients
were assumed to receive either iGlarLixi or
iDegLira until HbA1c progression (as simulated
with the UKPDS 68 equation [13]) returned to
study baseline values (i.e., 7.8%); at this point,
patients were assumed to receive treatment
intensification with bolus insulin injection
(rescue treatment). HbA1c reductions during
rescue treatment were conservatively approxi-
mated with data from the GetGoal Duo-2 trial
[16], which reported HbA1c reductions of 0.6%
when an insulin bolus was added to basal
insulin (with concomitant OADs). BMI was
assumed to remain identical between compara-
tor arms, and hypoglycemia rates were simu-
lated with CDM risk equations [17].
For all simulations, QALYs were assessed
using the minimum approach, where the low-
est-state utility of all concurrent comorbidities
was used and disutilities were added for events
that occur in that year, resulting in an annual
utility score for each simulated patient [12]. A
comprehensive set of utility and disutility
weightings were used for each model state and
complication experienced, obtained from pub-
lished literature (ESM Table S2) [18]. Direct
medical costs during each year of therapy in the
model were calculated on the basis of drug
acquisition costs, glucose monitoring costs,
management costs, and costs of T2DM compli-
cations (Table 2). In the European Union (EU),
iGlarLixi is available as two FRCs: 100 units/mL
insulin glargine plus 50 lg/mL lixisenatide
(Suliqua SoloStar pen 10–40), used to admin-
ister doses between 10 and 40 dose steps, and
100 units/mL insulin glargine plus 33 lg/mL
lixisenatide (Suliqua SoloStar pen 30–60), used
to administer doses between 30 and 60 dose
steps. The assumed cost of iGlarLixi in the first
year was estimated on the basis of assumed use
of the iGlarLixi 100/50 FRC for 3 months







Acquisition cost (1st year) 1018.21 1667.08
Acquisition cost (C 2nd
year)a
857.97 1667.08




Self-glucose monitoring 90.55 90.55
Annual cost (1st year) 1190.75 1839.62
Annual cost (C 2nd year) 1030.51 1839.62
Rescue therapy
Rapid-acting insulin 70.04 70.04
Additional needle use 37.62 37.62
First-line treatment 939.97 1749.07
Self-glucose monitoring 181.09 181.09
Annual cost 1228.72 2037.83
GBP British pound sterling, iDegLira insulin degludec plus
liraglutide, iGlarLixi insulin glargine 100 U/mL plus
lixisenatide
a All patients in iGlarLixi arm assumed to be receiving the
SoloStar pen 30–60 units (delivering dose steps from 30 to
60 units of insulin glargine in combination with 10–20 lg
lixisenatide) from 2nd year onwards
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followed by use of the iGlarLixi 100/33 FRC for
the remaining 9 months of that first year. From
the second year onward, it was assumed that
only the iGlarLixi 100/33 formulation was used.
All patients were assumed to be also receiving
metformin as oral diabetes therapy concur-
rently. A comprehensive list of costs associated
with complications (including cardiovascular
disease [CVD] complications, renal complica-
tions, acute events, eye disease, neuropathy,
foot ulcer, and amputations) was derived from
published literature, based on appropriate UK
national sources [18]. These costs (in 2019, Bri-
tish pound sterling [GBP]) were then applied to
each complication or event experienced by
patients in the model (ESM Table S3; ESM
Fig. S1).
Analyses
Incremental differences in costs, life years (LYs),
and QALYs were obtained for iGlarLixi versus
iDegLira arms. Incremental cost-effectiveness
ratio (ICER) estimates for iGlarLixi versus iDe-
gLira were calculated as the cost differential
divided by the difference in QALYs and reported
as costs per QALY. Cost impact was additionally
assessed using the net monetary benefit (NMB).
The NMB is calculated by multiplying the WTP
threshold (GBP £20,000/QALY) by the incre-
mental QALY and subtracts from this the
incremental cost. A positive NMB value indi-
cates that an intervention is cost-effective.
Multiple-scenario and one-way sensitivity
analyses were also performed to test the
robustness of the base case model assumptions.
The impact of the annual HbA1c progression
was tested assuming either a linear progression
of 0.15 or a progression according to the
Swedish National Diabetes Registry equations.
The influence of the treatment effect was eval-
uated using upper and lower estimates of HbA1c
progression in the iDegLira arm reported in the
ITC (lower bound, - 0.14% [i.e., change from
baseline for iDegLira, - 1.16%]; upper bound,
- 0.58% [i.e., change from baseline for iDe-
gLira, - 1.60]). A similar approach using upper
and lower estimates of BMI progression in the
iDegLira arm (lower bound, - 1.14 kg less than
iGlarLixi [i.e., BMI increase for iDegLira is
0.27 kg/m2]; upper bound, ? 0.67 kg less than
iGlarLixi [i.e., BMI increase for iDegLira is
0.91 kg/m2]) was tested. Finally, the cost of
rescue therapy in the iGlarLixi arm was
increased to match the iDegLira arm cost.
A probabilistic sensitivity analysis (PSA) was
also conducted to test uncertainty in the model
by random variation of key parameter inputs
within plausible distributions. The parameters
included in the PSA are the per-individual
characteristics, treatment efficacy, utility, and
cost of complications. Log-normal distributions
and 20% variation were applied to sample the
cost of complications. Treatment effects and
utility data were sampled following the beta
distribution, based on the estimated standard
error detailed in Table 1 (for treatment effects)
and on the standard deviation values reported
by Ramos et al. [18] (for utilities) (ESM
Table S2). For sampling individual baseline
characteristics, truncated normal distributions
were used following the mean and standard
deviations reported in ESM Table S1. The PSA
was performed using the base case settings and a
non-parametric bootstrapping approach in
which the progression of diabetes was simulated
in 1000 patients, each run through the model
1000 times, to calculate the mean and standard
deviation of costs, life expectancy, and quality-
adjusted life expectancy. Results are presented
in the cost-effectiveness plane, and as cost-ef-
fectiveness acceptability curves, giving the
probability that an intervention is cost-effective
for a range of WTP thresholds.
RESULTS
Base Case Analysis
In the base case analysis, the model predicted
similar discounted total LYs gained in the iDe-
gLira and iGlarLixi arms (13.177 versus 13.171,
respectively; Table 3). Treatment switch to res-
cue therapy was predicted to occur after 4 years
in the iGlarLixi arm and after 5 years in the
iDegLira arm. Discounted total QALYs gained
were slightly higher with iGlarLixi (iGlarLixi,
8.437; iDegLira, 8.422), driven by differences in
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non-severe hypoglycemic events with iGlarLixi
versus iDegLira (iGlarLixi, 1194 events per 1000
patient-years; iDegLira, 1201 events per 1000
patient-years; ESM Fig. S1). Costs were substan-
tially lower with iGlarLixi, largely due to the
difference in treatment acquisition costs
(iGlarLixi, £16,264; iDegLira, £27,042; Table 2).
In the base case analysis, iGlarLixi was less
expensive and produced similar QALYs; the
NMB of iGlarLixi was £11,030 (Table 3).
Scenario Analyses
The base case findings were not sensitive to
multiple variations in model inputs (Fig. 1).
With the exception of the scenario analysis
using the lower range of BMI, iGlarLixi was less
costly with similar QALYs gained versus iDe-
gLira in all scenarios (Fig. 1). The NMB for
iGlarLixi versus iDegLira ranged from £10,291
to £12,476 in most scenarios, but remained
positive in all (NMB was £2867 when cost of
rescue therapy was the same in each arm).
Probabilistic Sensitivity Analysis
In PSA, all iterations resulted in cost savings for
iGlarLixi, and 56% of iterations were in the
southeast quadrant of the cost-effectiveness
plan, indicating that iGlarLixi resulted in more
QALYs gained and cost savings versus iDegLira
(Fig. 2a). At a WTP threshold of £20,000/QALY,
iGlarLixi was deemed cost-effective in 100% of
cases (Fig. 2b).
DISCUSSION
This analysis demonstrates that iGlarLixi is cost-
effective compared with iDegLira in patients
with T2DM and inadequate glucose control on
GLP-1 RA and OADs, both in the base case and
in the multiple-scenario analyses. Life expec-
tancy and QALYs gained over the model dura-
tion were similar between treatment arms;
however, the iGlarLixi cohort had lower overall
costs, largely owing to the annual acquisition
costs for iGlarLixi being approximately £1000
less than iDegLira. QALYs gained were driven by
differences in non-severe hypoglycemic events.
Observations from the PSA further support the
robustness of the calculated ICER analyses, and
together suggest that iGlarLixi is a more cost-
effective treatment option than iDegLira for
patients with T2DM requiring treatment inten-
sification from GLP-1 RA therapy.
Despite the available evidence of efficacy and
safety, economic modeling enables payers to
make informed decisions regarding budgetary
impact and long-term cost-effectiveness. Con-
sequently, decision makers require a robust
health-economic analysis to further inform
treatment selection. Our estimation indicated
that iGlarLixi offered excellent value for money,
with similar QALYs and commensurate cost
savings compared with iDegLira, and the cost-
effective acceptability curve suggested that at a
WTP threshold of £20,000/QALY, iGlarLixi was
cost-effective in 100% of cases. The value of
iGlarLixi is also supported by NMB estimates, an
additional measure of cost-effectiveness that
indicates the estimated monetary value of the
benefit of a comparative intervention [19]. In
this analysis, the base case and all scenario
Table 3 Cost-effectiveness results (base case analysis)
iGlarLixi iDegLira
LY (years) 13.171 13.177
QALY (years) 8.437 8.422
Total costs (£) 30,011 40,742
iGlarLixi versus iDegLira
Incremental LY - 0.006
Incremental QALY 0.015
Incremental costs (£) - 10,730
ICER per QALY (£) Dominant
NMBa (£) 11,030
GBP British pound sterling, ICER incremental cost-ef-
fectiveness ratio, iDegLira insulin degludec plus liraglutide,
iGlarLixi insulin glargine 100 U/mL plus lixisenatide, LY
life year, NMB net monetary benefit, QALY quality-ad-
justed life year
a At local willingness-to-pay threshold of £20,000 per
QALY
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analyses had positive NMB estimates, indicating
that the cost savings with iGlarLixi outweighed
the value of the marginal differences in QALYs.
This analysis has several strengths. We
assessed lifetime costs and outcomes using the
IQVIA CDM, which has been extensively vali-
dated and is widely used in diabetes research
[10–12]. Model inputs were drawn largely from
locally appropriate published sources, and
extensive scenario analyses found the model
and results to be robust to variation in key
assumptions. However, certain limitations must
also be considered. Firstly, absolute HbA1c
treatment effect for iDegLira was derived from
relative HbA1c treatment effects estimated from
a previously published ITC [9]. As a result of
differences in the threshold used to define
hypoglycemia in iGlarLixi and iDegLira clinical
trials (\54 mg/dL and B 56 mg/dL,
respectively), an ITC was not conducted, and
hypoglycemia event rates from the trials were
used in CDM (summary reported in Home et al.
[9]). However, it should be noted that these
threshold definitions are similar. For BMI, there
was no significant difference between iGlarLixi
and iDegLira [9], so the same BMI increase is
applied in both arms in the base case. Robust-
ness of the cost-effectiveness conclusion was
confirmed in all scenario and sensitivity analy-
ses testing variations in the HbA1c, BMI, and
utilities values associated with occurrence of
hypoglycemia. Secondly, HbA1c reduction
during rescue therapy (- 0.6%) was conserva-
tively approximated with the basal-plus arm of
the GetGoal Duo-2 trial in the absence of other
evidence, and likely underestimated the treat-
ment effect. The BMI was assumed to remain
unchanged in the two treatment arms. Another
Fig. 1 NMBa results for iGlarLixi versus iDegLira:
summary of scenario analyses. BMI body mass index,
HbA1c glycated hemoglobin, iDegLira insulin degludec
plus liraglutide, iGlarLixi insulin glargine 100 U/mL plus
lixisenatide, NMB net monetary benefit, NSDR National
Swedish Diabetes Registry, NSHE non-severe hypo-
glycemic event. aNMB calculated based on assumed local
willingness-to-pay threshold of £20,000
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Fig. 2 Base case cost-effectiveness results: a cost-effectiveness plane; b cost-effectiveness acceptability curve. QALY quality-
adjusted life year
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limitation was to rely on relatively short-term
data (26 weeks) to extrapolate to long-term
projections. This issue is common in health-
economic analyses in diabetes but was addres-
sed with sensitivity and scenario analyses. Fur-
thermore, our analysis assessed only fixed-dose
GLP-1 RA and insulin combinations, and did
not compare free-dose combinations of the
individual agents. However, this is likely to
represent a cautious approach for a cost-effec-
tiveness analysis, as free-dose combinations are
known to be more expensive [20] and could be
associated with poorer treatment adherence [6];
consequently, they are likely to be less cost-ef-
fective compared with the FRC products used in
this analysis, although this would need to be
confirmed. Cost sources used in the model were
current at the time of publication, but obviously
may not reflect future changes in unit cost
pricing. Finally, we calculated costs in GBP as
the utility analysis was conducted from the
perspective of the UK NHS; extrapolation to
other markets and currencies cannot be
assumed.
CONCLUSION
Despite unavoidable assumptions inherent to
health-economic modeling, long-term analyses
are recommended by Health Technology
Assessment bodies to inform the decision-mak-
ing process and optimize budget allocation. In
conclusion, our analyses demonstrate that
iGlarLixi is a cost-effective treatment option
compared with iDegLira in patients with T2DM
whose HbA1c level is inadequately controlled
using GLP-1 RA and other OADs, with substan-
tial cost savings and comparable efficacy in the
UK.
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